These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1837 related articles for article (PubMed ID: 29083037)

  • 1. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.
    Liu J; Yang D; Wang X; Asare PT; Zhang Q; Na L; Shao L
    Front Cell Infect Microbiol; 2022; 12():774335. PubMed ID: 35444959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The gut microbiome is important in chronic liver disease].
    Christensen E
    Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol, liver disease and the gut microbiota.
    Bajaj JS
    Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
    Lang S; Schnabl B
    Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
    Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
    World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and the liver.
    Federico A; Dallio M; Caprio GG; Ormando VM; Loguercio C
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):385-398. PubMed ID: 28927250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
    Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
    Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
    Chen YH; Wu WK; Wu MS
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
    Wieland A; Frank DN; Harnke B; Bambha K
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
    Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
    Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
    Safari Z; Gérard P
    Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.